Chemical combination effects predict connectivity in biological systems
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Efforts to construct therapeutically useful models of biological systems require large and diverse sets of data on functional connections between their components. Here we show that cellular responses to combinations of chemicals reveal how their biological targets are connected. Simulations of pathways with pairs of inhibitors at varying doses predict distinct response surface shapes that are reproduced in a yeast experiment, with further support from a larger screen using human tumour cells. The response morphology yields detailed connectivity constraints between nearby targets, and synergy profiles across many combinations show relatedness between targets in the whole network. Constraints from chemical combinations complement genetic studies, because they probe different cellular components and can be applied to disease models that are not amenable to mutagenesis. Chemical probes also offer increased flexibility, as they can be continuously dosed, temporally controlled, and readily combined. After extending this initial study to cover a wider range of combination effects and pathway topologies, chemical combinations may be used to refine network models or to identify novel targets. This response surface methodology may even apply to non-biological systems where responses to targeted perturbations can be measured.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1707]
Experimental — accuracy not yet measuredIn the citing paper
“and that on general grounds [1706-1708,2142] such a strategy (for instance of combining a cell-permeable iron chelator with a cell-permeable antioxidant) might be expected to give a synergistic response.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1707]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Numerical recipes in C: the art of scientific computing
(1993) · Choice Reviews Online · doi:10.5860/choice.30-5638 · Cited by 17,933
David, F. N., & Tukey, J. W. (1977) · Biometrics · doi:10.2307/2529486 · Cited by 12,708
Network motifs: simple building blocks of complex networks.
Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D., & Alon, U. (2002) · Science · doi:10.1126/science.298.5594.824 · Cited by 7,368 · cited 2×
“Finally, because the simulated combination responses were insensitive to the reaction details, this methodology may even be extendable to non-biological network problems where responses to targeted perturbations can be measured (Milo et al , 2002).”
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683 · cited 1×
“…Saccharomyces cerevisiae (Zhang et al , 2005), which are built upon protein–DNA (Lee et al , 2002) and protein–protein (Ho et al , 2002) associations, supplemented by correlated changes in gene expression (Hughes et al , 2000) or protein abundances (Gygi et al , 1999) under differing conditions.”
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960 · cited 2×
“The observed synergies between sterol inhibitors are reflected in homozygous synthetic lethalities (Stark et al , 2006) that are internal to the pathway, and rapamycin’s synergy with terbinafine agrees with the reported interaction between TOR1 and ERG1.”
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry
Ho, Y., Gruhler, A., Heilbut, A., Bader, G. D., Moore, L., Adams, S.-L., Millar, A., Taylor, P., Bennett, K., Boutilier, K., et al. (2002) · Nature · doi:10.1038/415180a · Cited by 3,601
Self-citationIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
Functional Discovery via a Compendium of Expression Profiles
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00015-5 · Cited by 2,533
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Cited by
Items 101–200 of 279
Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion
Yılancıoğlu, K., & Cokol, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-48410-y · Cited by 41
Dunn, S., Eberlein, C., Yu, J., Gris‐Oliver, A., Ong, S. H., Yelland, U., Cureton, N., Staniszewska, A. D., McEwen, R. K., Fox, M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02482-9 · Cited by 43
Tosi, D., Pérez-Gracia, E., Atis, S., Vié, N., Combès, E., Gabanou, M., Larbouret, C., Jarlier, M., Mollévi, C., Torro, A., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4712-z · Cited by 43
Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Sahu, A. D., Lee, J. S., Wang, Z., Zhang, G., Iglesias‐Bartolomé, R., Tian, T., Wei, Z., Miao, B., Nair, N. U., Ponomarova, O., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188323 · Cited by 42
Bacterial responses to antibiotics and their combinations
Mitosch, K., & Bollenbach, T. (2014) · Environmental Microbiology Reports · doi:10.1111/1758-2229.12190 · Cited by 44
Systems biology in human health and disease
Lemberger, T. (2007) · Molecular Systems Biology · doi:10.1038/msb4100175 · Cited by 39
Chemical-genomic profiling: Systematic analysis of the cellular targets of bioactive molecules
Andrusiak, K., Piotrowski, J. S., & Boone, C. M. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.023 · Cited by 41
Networks from drug–drug surfaces
Yeh, P. J., & Kishony, R. (2007) · Molecular Systems Biology · doi:10.1038/msb4100133 · Cited by 42
Koizumi, Y., & Iwami, S. (2014) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-11-41 · Cited by 40
Harasym, T. O., Liboiron, B. D., & Mayer, L. D. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_13 · Cited by 39
Building a drug–target network and its applications
Lee, S., Park, K., & Kim, D. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903322234 · Cited by 39
Synergy Maps: exploring compound combinations using network-based visualization
Lewis, R., Guha, R., Korcsmáros, T., & Bender, A. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0090-6 · Cited by 39
Synergy: an old wisdom, a new paradigm for pharmacotherapy
Biavatti, M. W. (2009) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502009000300002 · Cited by 47
Development and analysis of an in vivo-compatible metabolic network of Mycobacterium tuberculosis
Fang, X. D., Wallqvist, A., & Reifman, J. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-160 · Cited by 43
MacLean, R. C. (2010) · Journal of Evolutionary Biology · doi:10.1111/j.1420-9101.2009.01888.x · Cited by 36
Searching for synergy in silico, in vitro and in vivo
Sucher, N. J. (2014) · Synergy · doi:10.1016/j.synres.2014.07.004 · Cited by 39
HENNEY, A. M., & Superti‐Furga, G. (2008) · Nature · doi:10.1038/455730a · Cited by 36
Owens, C. M., Mawhinney, C., Grenier, J. M., Altmeyer, R. M., Lee, M. S., Borisy, A. A., Lehár, J., & Johansen, L. M. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.32 · Cited by 37
Self-citationEmergence of the silicon human and network targeting drugs
Kolodkin, A. N., Boogerd, F. C., Plant, N. J., Bruggeman, F. J., Goncharuk, V. D., Lunshof, J. E., Moreno‐Sánchez, R., Yilmaz, N., Bakker, B. M., Snoep, J. L., et al. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.06.006 · Cited by 38
Kim, S., Masum, F., Kim, J.-K., Chung, H. J., & Jeon, J. S. (2019) · Lab on a Chip · doi:10.1039/c8lc01406j · Cited by 37
Dissection of Protein Interactomics Highlights MicroRNA Synergy
Zhu, W., Zhao, Y., Xu, Y., Sun, Y., Wang, Z., Yuan, W., & Du, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063342 · Cited by 37
Target-Independent Prediction of Drug Synergies Using Only Drug Lipophilicity
Yılancıoğlu, K., Weinstein, Z., Meydan, C., Akhmetov, A., Toprak, I., Durmaz, A., Iossifov, I. H., Kazan, H., Roth, F. P., & Cokol, M. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500276x · Cited by 34
Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations
Tang, J. P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7154-1_30 · Cited by 30
Lago, S. G., Tomasik, J., van Rees, G. F., Steeb, H., Cox, D., Rustogi, N., Ramsey, J. M., Bishop, J. A., Petryshen, T. L., Haggarty, S. J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau9093 · Cited by 30
Rønneberg, L., Cremaschi, A., Hanes, R., Enserink, J. M., & Zucknick, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab251 · Cited by 34
Spinozzi, G., Tini, V., Ferrari, A., Gionfriddo, I., Ranieri, R., Milano, F., Pierangeli, S., Donnini, S., Mezzasoma, F., Silvestri, S., et al. (2022) · Biomolecules · doi:10.3390/biom12070904 · Cited by 29
USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity
Nespolo, A., Stefenatti, L., Pellarin, I., Gambelli, A., Vinciguerra, G. L. R., Karimbayli, J., Barozzi, S., Orsenigo, F., Spizzo, R., Nicoloso, M. S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp6567 · Cited by 28
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies
Kotelnikova, E. A., Bernardo-Faura, M., Silberberg, G., Kiani, N. A., Messinis, D. E., Melas, I. N., Artigas, L., Schwartz, E., Mazo, I. A., Masso, M., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514543339 · Cited by 28
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Zanella, F., & Carnero, A. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0420-0 · Cited by 27
Mairuae, N., Palachai, N., & Noisa, P. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03930-z · Cited by 27
Grixti, J. M., O’Hagan, S., Day, P. J., & Kell, D. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00155 · Cited by 27
High-Throughput Screening for Drug Combinations
Shinn, P., Chen, L., Ferrer, M., Itkin, Z., Klumpp-Thomas, C. A., McKnight, C. G., Michael, S., Mierzwa, T., Thomas, C. J., Wilson, K. M., et al. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9089-4_2 · Cited by 31
Broghammer, F., Korovina, I., Gouda, M., Celotti, M., van Es, J. H., Lange, I., Brunner, C., Mircetic, J., Coppes, R. P., Gires, O., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01954-8 · Cited by 26
Lukas, M., Velten, B., Sellner, L., Tomska, K., Hüellein, J., Walther, T., Wagner, L., Muley, C., Wu, B., Oleś, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0846-5 · Cited by 26
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 27
Parsimonious Discovery of Synergistic Drug Combinations
Severyn, B. S., Liehr, R. A., Wolicki, A., Nguyen, K. H., Hudak, E. M., Ferrer, M., Caldwell, J. S., Hermes, J. D., Li, J., & Tudor, M. (2011) · ACS Chemical Biology · doi:10.1021/cb2003225 · Cited by 29
A High-Throughput Yeast Assay Identifies Synergistic Drug Combinations
Torres, N. P., Lee, A. Y., Giaever, G. N., Nislow, C., & Brown, G. W. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2012.503 · Cited by 28
Snyder, N. A., Kim, A., Kester, L., Gale, A. N., Studer, C., Hoepfner, D., Roggo, S. P., Helliwell, S. B., & Cunningham, K. W. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.118.200748 · Cited by 23
Kelly, P., Hadi-Nezhad, F., Liu, D. Y., Lawrence, T. J., Linington, R. G., Ibba, M., & Ardell, D. H. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007983 · Cited by 23
Ayurveda – Opportunities for Developing Safe and Effective Treatment Choices for the Future
Debnath, P. K., Banerjee, S., Debnath, P., Mitra, A., & Mukherjee, P. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800874-4.00020-9 · Cited by 30
Schmidt, L., Kling, T., Monsefi, N., Olsson, M. M., Hansson, C., Baskaran, S., Lundgren, B., Märtens, U., Häggblad, M., Westermark, B., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not111 · Cited by 27
mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
Kumari, A., Gesumaria, L., Liu, Y.-J., Hughitt, V. K., Zhang, X., Ceribelli, M., Wilson, K. M., Klumpp-Thomas, C. A., Chen, L., McKnight, C. G., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.156657 · Cited by 23
Kovaleva, K. S., Oleshko, O., Mamontova, E. M., Yarovaya, О. I., Zakharova, O. D., Zakharenko, A. L., Kononova, A. A., Dyrkheeva, N. S., Cheresiz, S. V., Pokrovsky, А. G., et al. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b01095 · Cited by 22
O’Hagan, S., Knowles, J. D., & Kell, D. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048862 · Cited by 22
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
Huang, L., Wang, J., Fang, B., Meric-Bernstam, F., Roth, J. A., & Ha, M. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-16933-6 · Cited by 21
Seyhan, A. A., Varadarajan, U., Choe, S. E., Liu, Y., McGraw, J., Woods, M. W., Murray, S., Eckert, A., Liu, W., & RYAN, T. E. (2011) · Molecular BioSystems · doi:10.1039/c0mb00294a · Cited by 21
Amirmahani, F., Ebrahimi, N., Molaei, F., Faghihkhorasani, F., Goharrizi, K. J., Mirtaghi, S. M., Boroujeni, M. B., & Hamblin, M. R. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14544 · Cited by 21
Exploring the Molecular Basis of Antifungal Synergies Using Genome-Wide Approaches
Agarwal, A. K., Tripathi, S., Xu, T., Jacob, M. R., Li, X., & Clark, A. M. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00115 · Cited by 21
Roelants, C., Giacosa, S., Pillet, C., Bussat, R., Champelovier, P., Bastien, O., Guyon, L., Arnoux, V., Cochet, C., & Filhol, O. (2018) · Oncotarget · doi:10.18632/oncotarget.25700 · Cited by 22
Aziz, R. K., Monk, J. M., Lewis, R. M., Loh, S. I., Mishra, A., Nagle, A. A., Satyanarayana, C., Dhakshinamoorthy, S., Luche, M., Kitchen, D. B., et al. (2015) · Scientific Reports · doi:10.1038/srep16025 · Cited by 21
Kashif, M., Andersson, C. R., Åberg, M., Nygren, P., Sjöblom, T., Hammerling, U., Larsson, R. L., & Gustafsson, M. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0430 · Cited by 20
Simulating Serial-Target Antibacterial Drug Synergies Using Flux Balance Analysis
Krueger, A., Munck, C., Dantas, G. A., Church, G. M., Galagan, J. E., Lehár, J., & Sommer, M. O. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147651 · Cited by 19
Self-citationRickles, R. J., Tam, W. F., Giordano, T. P., Pierce, L. T., Farwell, M., McMillin, D. W., Necheva, A. S., CROWE, D. F., Chen, M., Avery, W., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0925 · Cited by 21
Self-citationHemoglobin and hematocrit: an analysis of clinical accuracy. Case study of the anemic patient.
Keen, M. L. (1998) · PubMed · Cited by 23
Ansbro, M. R., Itkin, Z., Chen, L., Zahoránszky-Köhalmi, G., Amaratunga, C., Miotto, O., Peryea, T., Hobbs, C. V., Suon, S., Sá, J. M., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00110 · Cited by 18
Benson, H. E., Watterson, S., Sharman, J. L., Mpamhanga, C., Parton, A., Southan, C., Harmar, A. J., & Ghazal, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14037 · Cited by 18
Fotio, Y., Alaoui, A. A. E., Borruto, A. M., Acciarini, S., Giordano, A., & Ciccocioppo, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00711 · Cited by 19
Guided screen for synergistic three-drug combinations
Çakmak, M. Ç., Çetiner, S., Erdem, N., Bakan, F., & Cokol, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235929 · Cited by 20
Gilman, K. A. K., Han, S., Won, Y., & Putnam, C. W. (2021) · BMC Cancer · doi:10.1186/s12885-021-07963-w · Cited by 18
Melnyk, J. E., Steri, V., Nguyen, H. G., Hwang, Y. C., Gordan, J. D., Hann, B. C., Feng, F. Y.-C., & Shokat, K. M. (2022) · Oncogene · doi:10.1038/s41388-022-02179-z · Cited by 17
Research on Human Body Movement Posture Based on Inertial Sensor
Zhang, L. (2018) · International Journal Bioautomation · doi:10.7546/ijba.2018.22.2.179-186 · Cited by 16
Functional patient-derived cellular models for neuropsychiatric drug discovery
Lago, S. G., Tomasik, J., & Bahn, S. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01243-8 · Cited by 16
Kell, D. B. (2021) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2021.01.001 · Cited by 16
Prioritizing Molecular Biomarkers in Asthma and Respiratory Allergy Using Systems Biology
Cremades‐Jimeno, L., de Pedro, M. Á., López-Ramos, M., Sastre, J., Mínguez, P., Mahíllo, I., Baos, S., & Cárdaba, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640791 · Cited by 17
A Point of Inflection and Reflection on Systems Chemical Biology
Johnson, E. O., & Hung, D. T. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00714 · Cited by 16
Iannuzzi, S., & von Kleist, M. (2021) · Viruses · doi:10.3390/v13071354 · Cited by 15
Sui, J., Cotard, S., Andersen, J., Zhu, P., Staunton, J. E., Lee, M., & Lin, S. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0312 · Cited by 18
Self-citationCokol, M. (2013) · Current Drug Discovery Technologies · doi:10.2174/1570163811310020003 · Cited by 15
Future perspectives for mTOR inhibitors in renal cell cancer treatment
Czarnecka, A. M., Kornakiewicz, A., Lian, F., & Szczylik, C. A. (2015) · Future Oncology · doi:10.2217/fon.14.303 · Cited by 14
Dakik, P., McAuley, M., Chancharoen, M., Mitrofanova, D., Rodriguez, M. E. L., Junio, J. A. B., Lutchman, V., Cortes, B., Simard, É., & Titorenko, V. I. (2019) · Oncotarget · doi:10.18632/oncotarget.26553 · Cited by 15
Kell, D. B., & Pretorius, E. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/054734 · Cited by 14
Combination therapy for the treatment of pulmonary mold infections
McCarthy, M. W., Petraitis, V., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1325322 · Cited by 15
Zaharieva, M. M., Trochopoulos, A., Dimitrova, L. L., Berger, M. R., Najdenski, H. M., Konstantinov, S., & Kroumov, A. D. (2018) · International Journal Bioautomation · doi:10.7546/ijba.2018.22.2.87-106 · Cited by 13
Boik, J. C., & Newman, R. A. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-13 · Cited by 13
Shiraishi, R., Cancila, G., Kumegawa, K., Torrejon-Diaz, J., Basili, I., Bernardi, F., da Silva, P. B. G., Wang, W.-C., Chapman, O. S., Yang, L., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.05.013 · Cited by 12
Efficient discovery and optimization of complex high-throughput experiments
Cawse, J. N., Gazzola, G., & Packard, N. H. (2010) · Catalysis Today · doi:10.1016/j.cattod.2010.05.043 · Cited by 12
Subtraction Procedure for Power-line Interference Removal from ECG signals with High Sampling Rate
Mihov, G. S. (2018) · International Journal Bioautomation · doi:10.7546/ijba.2018.22.2.147-158 · Cited by 12
Alterations of chemotherapeutic pharmacokinetic profiles by drug–drug interactions
Mani, S., Ghalib, M., Chaudhary, I., & Goel, S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902753212 · Cited by 12
Ramírez-Mejía, J. M., Aguilera-Gálvez, C., Kema, G. H. J., Valencia-Riascos, L. M., Zapata-Henao, S., Gómez, L. A., & Villegas-Escobar, V. (2024) · Tropical Plant Pathology · doi:10.1007/s40858-024-00677-x · Cited by 11
Existence of Inverted Profile in Chemically Responsive Molecular Pathways in the Zebrafish Liver
Ung, C. Y., Lam, S. H., Zhang, X., Li, H., Ma, J., Zhang, L., Li, B., & Gong, Z. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027819 · Cited by 11
Optimal stepwise experimental design for pairwise functional interaction studies
Casey, F., Cagney, G., Krogan, N. J., & Shields, D. C. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn472 · Cited by 11
Quantitative bioassay to identify antimicrobial drugs through drug interaction fingerprint analysis
Weinstein, Z., & Zaman, M. H. (2017) · Scientific Reports · doi:10.1038/srep42644 · Cited by 12
The optimization of combinatorial drug therapies: Strategies and laboratorial platforms
Wang, B., Warden, A. R., & Ding, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.023 · Cited by 11
González‐Durruthy, M., Concu, R., Vendrame, L. F. O., Zanella, I., Ruso, J. M., & Cordeiro, M. N. D. S. (2020) · Molecules · doi:10.3390/molecules25225425 · Cited by 11
A novel role for jun N-terminal Kinase signaling in olfactory sensory neuronal death
Gangadhar, N. M., Firestein, S., & Stockwell, B. R. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.04.013 · Cited by 11
Self-citationMultidimensional profiling in the investigation of small-molecule-induced cell death
Wolpaw, A. J., & Stockwell, B. R. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801430-1.00011-1 · Cited by 10
“Lehar and colleagues created dose matrices for combinations of 10 sterol inhibitors in yeast (Lehar et al., 2007).”
BackgroundSelf-citationModeling synergistic drug inhibition of Mycobacterium tuberculosis growth in murine macrophages
Fang, X. D., Wallqvist, A., & Reifman, J. (2011) · Molecular BioSystems · doi:10.1039/c1mb05106g · Cited by 10
Cancer network activity associated with therapeutic response and synergism
Serra-Musach, J., Mateo, F., Capdevila-Busquets, E., Ponce, G. R. D. G., Zhang, X., Guha, R., Thomas, C. J., Grueso, J., Villanueva, A., Jaeger, S., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0340-x · Cited by 10
Maqbool, T., Hadi, F., Razzaq, S., Naz, S., Aftab, S., Khurshid, S., Awan, S. J., Nawaz, A., Abid, F., & Malik, A. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.3.843 · Cited by 10
Diamant, I., Eldar, Y. C., Rokhlenko, O., Ruppin, E., & Shlomi, T. (2009) · Molecular BioSystems · doi:10.1039/b823287n · Cited by 12
Aziz, R. K., Khaw, V. L., Monk, J. M., Brunk, E., Lewis, R., Loh, S. I., Mishra, A., Nagle, A. A., Satyanarayana, C., Dhakshinamoorthy, S., et al. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00958 · Cited by 11
Recent advances in quantitative high throughput and high content data analysis
Moutsatsos, I. K., & Parker, C. N. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1154036 · Cited by 10
Cava, C., & Castiglioni, I. (2019) · Gene · doi:10.1016/j.gene.2019.02.064 · Cited by 10
Li, L., Zhang, N., & Li, S. (2010) · Chinese Science Bulletin · doi:10.1007/s11434-010-4067-6 · Cited by 10
In silico signaling modeling to understand cancer pathways and treatment responses
Kunz, M., Jeromin, J., Fuchs, M., Christoph, J., Veronesi, G., Flentje, M. P., Nietzer, S., Dandekar, G., & Dandekar, T. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz033 · Cited by 10
Godínez, A. K. K., Regalado‐González, C., Villicaña, C., Heredia, J. B., Valdez-Torres, J. B., Muy‐Rangel, M. D., Escamilla‐García, M., & León‐Félix, J. (2025) · Molecules · doi:10.3390/molecules30173552 · Cited by 9
Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
Hany, D., Zoetemelk, M., Bhattacharya, K., Nowak-Sliwinska, P. M., & Picard, D. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04730-x · Cited by 9
Dixon, S. J., & Stockwell, B. R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.353 · Cited by 9
Self-citationIt, D., Zhilyaev, S. Y., Alekseeva, O. S., Кривченко, А. И., Piantadosi, C. A., & Gasier, H. G. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00063-5 · Cited by 9
Folkesson, E., Sakshaug, B. C., Hoel, A. D., Klinkenberg, G., & Flobak, Å. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1112831 · Cited by 9
Metadata
- Authors
- Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., Lee, M. S., Borisy, A. A., Stockwell, B. R., & Keith, C. T.
- Affiliations
- Boston University (US)
- Columbia University (US)
- Corresponding author
- Lehár, Joseph
- Venue
- Molecular Systems Biology
- Published
- 2007-02-27
- Volume
- 3
- Issue
- 1
- Pages
- 80-80
- ISSN
- 1744-4292 (ISSN-L)
- PMC
- PMC1828746
- OpenAlex
- W1975728616
- Cited by
- 275
- References
- 68
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 15 · 2022: 9 · 2021: 14 · 2020: 11 · 2019: 17 · 2018: 18 · 2017: 11 · 2016: 15 · 2015: 18 · 2014: 22 · 2013: 14 · 2012: 13
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Systems Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OpenBU (Boston University) (submittedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- synergistic effect, response surface, pathway modeling, inhibitors, dose-response relationship, yeast, cancer cells, network inference, chemical probes
- MeSH terms
- Computer Simulation, Drug Combinations, Drug Synergism, Humans, Models, Biological, Saccharomyces cerevisiae, Sterols, Models, Statistical, Gene Expression Regulation, Fungal, HCT116 Cells, Systems Biology, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.